Literature DB >> 1405951

[Preventive or therapeutic parathyroidectomy in primary hyperparathyroidism].

P Buchmann1, M Lüscher, F Largiadèr, W Weder.   

Abstract

The only causal treatment of primary hyperparathyroidism (PHPT) is parathyroidectomy. There are indications in the literature that despite operation expectation of life is shortened because of an increased frequency of cardiovascular and malignant diseases leading to the recommendation for early surgery even in uncomplicated PHPT. It is easier to convince an asymptomatic patient of an operation when he is informed about complications and consequences of an expectative attitude. Therefore, we reviewed our 71 patients operated upon during a 4-year-interval, 58 of whom were followed-up. During 82 operations 115 pathologically altered parathyroid glands were removed. Two persistent paralyses of the recurrent nerve occurred, however, without alteration of the voice. Follow-up of 82% of patients revealed 2 cases of recurrent nephrolithiasis (1 hypercalcaemia, 1 normocalcaemia). Three (5%) true recurrences were found, but neither a pancreatitis nor a peptic ulcer was noted during long-term follow-up. None of the 137 patients operated for a bleeding or perforated peptic ulcer during the last 10 years and 1 of 55 patients with acute pancreatitis during the past 8 years suffered from a PH-PT. However, morbidity and mortality of these two conditions was high. Although correlation to PHPT was low we recommend early operation of PHPT because of the low morbidity rate, zero lethality and reduced expectation of life.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405951     DOI: 10.1007/bf00189471

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  13 in total

1.  True recurrence of hyperparathyroidism: proposed criteria of recurrence.

Authors:  H Muller
Journal:  Br J Surg       Date:  1975-07       Impact factor: 6.939

2.  1.5 T MRI, CT, ultrasonography and scintigraphy in hyperparathyroidism.

Authors:  G K von Schulthess; W Weder; N Goebel; P Buchmann; A Gadze; N Augustiny; F Largiadèr
Journal:  Eur J Radiol       Date:  1988-08       Impact factor: 3.528

3.  [Can truncal vagotomy still be justified?].

Authors:  A Olah; P Buchmann; F Largiadèr
Journal:  Helv Chir Acta       Date:  1989-01

4.  [Hypergastrinemia, hypercalcemia and stomach secretion (studies in chronic dialysis patients with secondary hyperparathyroidism before and after parathyroidectomy)].

Authors:  I Klempa; H H Malluche; G Feurle; E Wünsch
Journal:  Langenbecks Arch Chir       Date:  1974

5.  Treatment of primary hyperparathyroidism.

Authors:  D C Purnell; D A Scholz; L H Smith; G W Sizemore; M B Black; R S Goldsmith; C D Arnaud
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

6.  [Asymptomatic hyperparathyroidism. An indication for surgery?].

Authors:  N Augustin; P K Wagner; M Rothmund
Journal:  Dtsch Med Wochenschr       Date:  1987-04-17       Impact factor: 0.628

7.  [Lessons from reoperations in 55 patients with primary hyperparathyroidism].

Authors:  M Rothmund; P K Wagner; H Seesko; A Zielke
Journal:  Dtsch Med Wochenschr       Date:  1990-10-19       Impact factor: 0.628

8.  [Clinical management of persistent primary hyperparathyroidism].

Authors:  H J Buhr; D Flentje; S Fischer; C Herfarth
Journal:  Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir       Date:  1990

9.  [Clinical aspects of acute pancreatitis].

Authors:  M Röthlin; C Strittmatter; S Geroulanos; F Largiadèr
Journal:  Schweiz Med Wochenschr       Date:  1989-05-27

Review 10.  [Questionable hyperparathyroidism: diagnostic value of thallium-technetium subtraction scintigraphy].

Authors:  S Roth; W Schaden; H Brandt; L E Feinendegen; P Rathert
Journal:  Urologe A       Date:  1989-11       Impact factor: 0.639

View more
  1 in total

1.  European endocrine surgery in the 150-year history of Langenbeck's Archives of Surgery.

Authors:  Henning Dralle; A Machens
Journal:  Langenbecks Arch Surg       Date:  2010-03-09       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.